Psilocybin molecule:

Image from PubChem

Psilocybin Clinical Trials

The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation

To see complete record on, please visit this link

Id: NCT05220410

Organisation Name: Sheppard Pratt Health System

Overal Status: Recruiting

Start Date: March 28, 2022

Last Update: December 30, 2022

Lead Sponsor: Sheppard Pratt Health System

Brief Summary: This study aims to explore the safety and tolerability of a single dose of psilocybin (25mg) administered under supportive conditions to adult participants with TRD and chronic suicidal ideation

  • Treatment Resistant Depression
  • Suicidal Ideation

Total execution time in seconds: 0.18052005767822